Skip to main content
. 2017 Jul 26;8(52):90430–90443. doi: 10.18632/oncotarget.19563

Figure 1. Kaplan-Meier progression-free survival (PFS) curves according to the treatment dose of afatinib.

Figure 1

Patients receiving 40 mg and < 40 mg of afatinib during the first 6 months are represented by the solid (red) and dashed (blue) lines, respectively.